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ABSTRACT 
 
Mitochondria play a central role in cellular energy metabolism, and they supply 
most cellular adenosine triphosphate (ATP). During production of ATP, 
mitochondria also produce reactive oxygen species that could be damaging to 
mitochondria and to other cellular compartments. To limit and control the 
production of excessive reactive oxygen production, mitochondria have developed 
several quality control mechanisms that ensure mitochondrial integrity. 
Degradation of mitochondria through autophagy is the last step in mitochondrial 
quality control. Although mitochondrial dysfunctions are described in many human 
diseases including neurological diseases, diabetes, and cancer, there is little 
known about whether mitophagy plays any role in the etiology of these diseases.  
Partly this could be explained by the fact that for a long time mitophagy has been 
considered a nonselective process. Now several lines of evidence suggest that 
mitophagy is a steady state process, and in metabolically active tissues, the half-
life of mitochondria is as low as two days. Possibly another reason for the slow 
progress in mitophagy research has been the lack of easily applicable and 
sensitive methods for mitophagy detection, and most mitophagic research has 
been done in settings of extreme mitochondrial stress. For example, carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), an uncoupling agent of the 
mitochondrial proton gradient, has been extensively used.  Although CCCP and 
other global mitochondrial stressors are excellent inducers of mitophagy, they 
affect the entire mitochondrial pool, and in most cases, do not recapitulate any 
given physiological or pathophysiological condition. Here we report a sensitive and 
highly quantifiable method for detection of mitophagy and autophagy in parallel 
that could be applied to physiological conditions of cells. This method relies on 
lysosomal delivery of mitochondrial targeted pH-sensitive Rosella biosensors and 
could reliably detect even very weak induction of mitophagy. Moreover, using this 
method we identified that pyruvate metabolism in mitochondria induces mitophagy. 
This mitophagy is mediated by pseudohypoxic induction of hypoxia inducible factor 
1α. Interestingly, we discovered that even close to physiological levels of glucose 
can induce this pathway. Importantly, this process is completely blocked with 
pharmacological inhibitors of the mitochondrial pyruvate carrier. 
Thiazolidinediones, a class of insulin sensitizing medications, are known to inhibit 
the mitochondrial pyruvate carrier. Here, we show that thiazolidinediones are 
effective inhibitors of pyruvate induced pseudohypoxia. This observation is 
particularly interesting since thiazolidinediones are actively prescribed. Whether 
this phenomenon is clinically relevant remains to be studied. 
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INTRODUCTION 
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Overview of mitochondria 
Mitochondria are essential organelles that reside within the cytoplasm of every 
eukaryotic cell except for some specialized cells such as erythrocytes and lens 
cells1, 2. Mitochondria are segregated from the cytoplasm with double membranes: 
a porous mitochondrial outer membrane (MOM) and impermeable inner 
membrane (MIM). The space between those two membranes is called the 
intermembrane space (IMS), and the mitochondrial core is called the matrix. 
Mitochondria are functionally multifaceted and are pivotal in cellular metabolism. 
Unlike other organelles in eukaryotic cells, mitochondria possess circular 
deoxyribonucleic acid (DNA) and DNA replication machinery. Phylogenetic 
analysis of mitochondrial genes 3, 4 suggests that mitochondria evolved from alpha 
proteobacteria after engulfment by an eukaryotic ancestor. This engulfment 
eventually evolved into an endosymbiotic state, where most of the genes encoding 
mitochondrial proteins were transferred to the nucleus of the cell, and only 13 out 
of  1000+ proteins5  are encoded in circular mitochondrial DNA (mtDNA). 
Mitochondria have structurally distinct ribosomes that translate mtDNA encoded 
genes. These 13 genes encode essential oxidative phosphorylation proteins. The 
rest of the mitochondrial proteome requires cytoplasmic translation and import of 
proteins.  Importantly, there is a great degree of dynamic and rapid regulation of 
both mitochondrial and cytosolic translation of mitochondrial proteins6.  For the 
import processes, most mitochondrial proteins in the cytoplasm are translated with 
a mitochondrial localization presequence, which directs them to mitochondria 
where the presequence is proteolytically cleaved upon import 7, 8.  Mitochondrial 
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outer membrane proteins lack this presequence and instead contain mitochondria 
targeting sequences within mature proteins. These targeting sequences are 
recognized by mitochondrial translocase of outer membrane (TOM)-associated 
receptors. After crossing the outer membrane, these newly imported proteins are 
directed to either Translocase of Inner Membrane 23 complex (TIM23) for import 
to the mitochondrial matrix, or to Translocase of Inner Membrane 22 complex 
(TIM22), that facilitates insertion of those proteins into the inner membrane. 
Importantly, the mitochondrial proton gradient is essential for both inner membrane 
translocase complexes9.  Mitochondria also rely on other cellular compartments 
and organelles for their lipid needs. Although some of the mitochondrial lipids such 
as phosphatidylglycerol and cardiolipin are mitochondria specific and are 
synthesized in mitochondria10, 11, other lipids are imported from the endoplasmic 
reticulum (ER).  
 
Mitochondria in energy production 
Historically, mitochondria have been looked at primarily as powerhouses of 
cells, although now their diverse functions are widely recognized. Mitochondria are 
involved in many aspects of cellular processes such as fatty acid and amino acid 
metabolism, iron12 and calcium homeostases13, induction of apoptosis14, and 
autophagy15. Perhaps the most recognized function of mitochondria is the 
generation of ATP through a complex and highly regulated process of the 
tricarboxylic acid cycle (TCA) and oxidative phosphorylation. Through a series of 
reactions in the tricarboxylic acid cycle, acetyl-CoA, derived from different sources, 
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is oxidized to carbon dioxide and water. During these reactions, the TCA generates 
reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine 
dinucleotide (FADH2), which transfer their electrons to the electron transfer chain 
(ETC) in the mitochondrial inner membrane. The ETC is comprised of four different 
protein complexes termed complex I through IV. Through redox reactions complex 
I accepts two electrons from NADH and simultaneously pumps protons into the 
mitochondrial intermembrane space. Electrons from FADH2 are accepted by 
complex II, while complexes III and IV transfer additional protons to the 
intermembrane space. This proton gradient generated by the ETC across the 
mitochondrial inner membrane is released by complex V (ATP synthase) that uses 
this electrochemical gradient to phosphorylate adenosine diphosphate (ADP) to 
triphosphate (ATP), the main energy carrier molecule of eukaryotic cells. This 
electrochemical gradient is also used in generation of heat in brown and beige 
adipocytes, through the actions of Uncoupling Protein 1(UCP1). 
Mitochondria as reactive oxygen species (ROS) source 
The electron transport chain is also a significant source of reactive oxygen 
species production and it is estimated that up to 2% of oxygen consumed is 
converted to reactive oxygen species (ROS). ROS formation in mitochondria is a 
result of electron leak from the ETC and subsequent reduction of molecular 
oxygen. The ETC primarily generates superoxide (O2 -) by reduction of oxygen at 
complexes I and III, where superoxide coming from complex I is released to the 
matrix, while complex III produced superoxide is found in both matrix and 
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intermembrane space. Historically, ROS were considered harmful, although now 
several lines of evidence suggest that ROS  have important physiological roles and 
serve as signaling molecules16.  For example, ROS production is required for 
proper function of some growth factors, and inhibition of ROS production blocks 
their downstream tyrosine kinase signaling17, 18.  Mitochondrial ROS also regulate 
several physiological responses. Particularly, mitochondrial ROS is critical in the 
hypoxic response19-21, induction of autophagy22, inflammation response23, 24 and 
vascular constriction25. Although well-regulated production of ROS is important in 
cellular signaling, several conditions could increase production of ROS and inflict 
significant oxidative damage both to mitochondria and to other cellular 
compartments. Increased levels of NADH in the matrix accompanied by decreased 
oxidative phosphorylation (OXPHOS) activity could result in excessive superoxide 
production. In addition, high membrane potential causes increased ROS 
production by reverse electron transport26. Importantly, reverse electron transport 
generated ROS recently have been implicated in reperfusion injury27. Mitochondria 
originated oxidative stress can be damaging to almost all biological 
macromolecules (DNA, proteins, and lipids), and mitochondrial ROS have been 
implicated in many disease states and aging.  Oxidative damage to DNA is thought 
to be one of the mechanisms of mutagenesis and eventually carcinogenesis28, 29, 
and many cancer types exhibit increased ROS production30. Moreover, ROS is 
also known to activate the MAPK/Erk1/2 pathway in some cancer types, which 
increases cell proliferation31, 32.  Interestingly, different ROS are shown to have 
countering effects on cell proliferation: Low doses of hydrogen peroxide coupled 
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with superoxide are known to induce proliferation, while high levels of hydrogen 
peroxide promote senescence33. ROS is also implicated in type 2 diabetes and it 
is well established that hyperglycemia induces increased ROS production34, 35. 
Furthermore, β cell dysfunction during diabetes could be attributed to chronic 
hyperglycemic induction of  ROS production36. ROS also can act in peripheral 
tissues by interfering with insulin receptor signaling 37 and by activating the JNK 
pathway that promotes peripheral insulin resistance. Consistent with this theory, it 
has been shown that antioxidant therapy could reverse the progression of type 2 
diabetes38, 39. Another major area of ROS related pathologies are neurological 
diseases. For example, Alzheimer’s disease (AD) is characterized by abnormal 
levels of oxidative damage40, 41 and mitochondria associated mutations42, 43. 
Amyotrophic lateral sclerosis (ASL), another debilitating disease,   is directly linked 
to mitochondria and ROS and 20% of familial cases of ALS are known to arise 
from mutations in the superoxide dismutase gene44. Furthermore, mitochondrial 
dysfunction and ROS are also involved in Parkinson’s disease, another prevalent 
pathology. Growing evidence suggests that mutations in familial forms of 
Parkinson’s disease are often accompanied by increased ROS production and 
decreased activity of complex I45-47.  ROS are also thought to be central in aging 
theory48-50 as they contribute to the decline of mitochondrial function over time. 
Mitochondrial dysfunction not related to excessive ROS production is also 
implicated in human diseases.  For example, dysregulation of TCA cycle enzymes 
can lead to selective accumulation of metabolites that are implicated in progression 
of various cancers, mainly by inhibition of enzymes responsible for degradation of 
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hypoxia inducible factor 1α (HIF-1α). For example, mutations in the succinate 
dehydrogenase complex and fumarate hydratase lead to pheochromocytomas and 
paragangliomas51-54.  
Mitochondrial quality control 
Unlike any other organelle in eukaryotic cells, mitochondria have their own 
DNA that encodes 13 proteins for the ETC, 2 mitochondrial ribosomal RNAs, and 
22 transfer RNAs. The proximity of ROS generation sites makes mitochondrial 
DNA susceptible to oxidative damage. It has been estimated that mutation rates in 
mtDNA are 10 to 15 times higher than in nuclear DNA55, 56. Over time this damage 
contributes to the decrease in mitochondrial function. Apart from mtDNA, 
mitochondrial proteins and lipids also sustain significant oxidative damage. In 
particular, the ETC is known to be a target of oxidative modifications57 and  there 
is an increase of oxidative damage to the ETC complexes with age58. In addition, 
proteins that are not associated with ETC are also known to undergo oxidative 
modifications. For example, mitochondrial aconitase is sensitive to oxidative 
stress59, and upon being damaged could also contribute to ROS production60. 
Alpha ketoglutarate dehydrogenase is another target for ROS and subsequent 
impairment is implicated in Alzheimer’s disease61, 62.  Other significant targets for 
oxidative damage are mitochondrial lipids. Oxidative damage to lipids on 
mitochondrial membranes is shown to impair mitochondrial function63, 64. 
As a source and a target of ROS, mitochondria possess several quality control 
mechanisms that ensure the mitochondrial integrity and homeostasis. 
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Mitochondrial quality control mechanisms can be divided into four distinct parts: 1) 
Regulation and detoxification of reactive oxygen species by antioxidant defense 
mechanisms, 2) Identification and repair/degradation of misfolded or oxidized 
proteins by mitochondrial resident proteases, 3) Segregation of damaged or 
excessive proteins into distinct compartments and budding off of mitochondria, and 
4) destruction of a whole mitochondria by means of autophagy.
Mitochondrial antioxidant defense 
In physiological states, production of ROS by the ETC in mitochondria is highly 
regulated by several mechanisms. Mitochondrial Uncoupling Proteins 2 and 3 ( 
UCP 2-3) are thought to limit excessive ROS production by decreasing the proton 
gradient formation65. Moreover, it has been shown that UCPs are activated by 
ROS, which serve as a negative feedback mechanism. Superoxide formed at the 
ETC is converted to hydrogen peroxide by mitochondrial resident protein 
superoxide dismutase (SOD2). Hydrogen peroxide, in turn, is converted  to water 
and oxygen by the action of catalase enzyme, which is also present in 
mitochondria of some tissues66. Mitochondria also have other enzymes with 
antioxidant properties such as peroxiredoxins67, which in combination with 
thioredoxin and thioredoxin reductase68 catalyze conversion of hydrogen peroxide 
into water. It has been estimated that the superoxide dismutase and 
peroxiredoxin/thioredoxin/thioredoxin reductase system are the main 
mitochondrial antioxidant defense systems69. In addition to proteins that catalyze 
conversion of ROS to water and molecular oxygen, a major antioxidant defense 
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system is tripeptide glutathione70 which is present in high concentrations in 
mitochondria as well as in cytosol and nuclei. Glutathione can directly scavenge 
ROS and act as a cofactor for some enzymes involved in antioxidant defense such 
as glutathione peroxidase. 
Mitochondrial proteases 
Mitochondria have three major classes of ATP-dependent proteases, Lon 
protease, Clp-like, and AAA-protease71. The last two are found in the matrix and 
on the inner mitochondrial membrane and facilitate degradation of misfolded and 
oxidized proteins72, 73. Hydrophobic surfaces are thought to serve as a recognition 
domain for both proteases. Lon protease plays a critical role in the degradation of 
oxidized aconitase74 , Cytochrome C Oxidase Subunit 4 Isoform 1, Succinate 
Dehydrogenase Subunit 5, and other damaged proteins75. Furthermore, Lon 
deficient cells exhibit significant mitochondrial defects that lead to cell death76. 
Mitochondrial proteases have been shown to participate in numerous other 
aspects of mitochondrial integrity such as the mitochondrial unfolded protein 
response, mitochondrial morphology changes, mitophagy, and apoptosis75. 
Mitochondria-derived vesicles and compartments 
In 2008, Neuspiel and colleagues identified a new class of vesicular transport 
from mitochondria and peroxisomes that is cargo selective77. Importantly, only a 
subset of mitochondria-derived vesicles (MDV) was targeted to peroxisomes. In 
2012, the same group identified the second destination for MDV as the lysosome78. 
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Interestingly, these vesicles form after oxidative stress induction and bud directly 
from respiring mitochondria that do not yet exhibit excessive ROS damage signs. 
It appears that actively respiring mitochondria without any additional oxidative 
stress can produce hundreds of MDVs, indicating a steady state process. Later, it 
was determined that MDVs are enriched for oxidized mitochondrial proteins79. 
Moreover, PINK1 and Parkin have been shown to play a direct role in MDV 
formation80. This finding is particularly interesting since it appears that these 
proteins are involved in multistage mitochondrial quality control and can mediate 
MDV formation as well as mitophagy. A similar pathway of vesicular transport from 
mitochondria to lysosomes, called mitochondria-derived compartments (MDC), 
has been recently identified in budding yeast81. Although similar in concept, these 
two pathways are distinct in their cargo selection. MDCs contain mainly 
mitochondrial outer, and a subset of inner membrane proteins belonging to the 
carrier family. Importantly, inhibition of the MDC pathway results in deterioration of 
mitochondrial membrane potential, suggesting that MDCs play a protective role 
and are part of mitochondrial quality control. 
Degradation of mitochondria by autophagy 
The above mentioned mitochondrial quality controls are nondestructive ways 
to maintain mitochondrial integrity. It is presumed that if these mechanisms fail to 
preserve mitochondrial homeostasis, parts of mitochondria are targeted for 
destruction by autophagy, a process of degradation in which cells catabolize some 
parts of the cytosol and the organelles through delivery to lysosomes. General 
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autophagic pathways are conserved through yeast to mammals and involve the 
ATG proteins.  Currently, about 37 ATG proteins have been identified82. The most 
prevalent form of autophagy, termed macroautophagy, is a nonselective process 
that is triggered by starvation and provides cells with necessary nutrients. During 
general autophagy, the phagophore membrane, also called the isolation 
membrane, engulfs a portion of cytoplasm and segregates its contents. Eventually, 
the phagophore membrane closes to form double membrane vesicles known as 
autophagasomes. Autophagasomes then fuse either with other autophagasomes 
or lysosomes where their contents are degraded by lysosomal enzymes. The 
substrates later are released as free amino acids and other molecules. Mitophagy 
is a special form of autophagy, where mitochondria are selectively targeted for 
lysosomal degradation by the autophagic machinery. The primary role of 
mitophagy is to eliminate defective and old mitochondria. Mitophagy is also critical 
in erythrocyte development and destruction of paternal mitochondria during 
conception. In early research, lysosomal degradation of mitochondria was thought 
to be a “bystander” process, where induction of general autophagy affected some 
mitochondria. The first case of mitophagy was reported in 1962 by Ashford and 
Porter83, where the authors described mitochondria in the lysosomes of  hepatic 
tissues after glucagon treatment. Later, it was established that mitochondria could 
be targeted for degradation independently of other organelles such as 
peroxisomes. Notably, during starvation mammalian mitochondria are 
preferentially spared from autophagic destruction by elongation and formation of 
interconnected networks, thus escaping engulfment by the phagophore     memb-
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rane84. Significant progress in the identification of mediators of mitophagy has 
been accomplished in yeast systems, where genetic screens identified close to 40 
proteins that are required for mitophagy, but not for general autophagy85. For 
example, ATG32  localizes to mitochondria and recruits the canonical autophagic 
machinery86. Another protein involved in mitophagy in yeast is ATG11, which 
functions as a cargo receptor between mitochondria and ATG887. A mammalian 
homologue of ATG32 was recently discovered88, 89, but a homologue of ATG11 
has not yet been identified. In yeast, mitochondrial degradation is closely regulated 
by the carbon source90, and mitophagy does not take place when a carbon source 
is non fermentable. In contrast, there is robust mitophagy with fermentable carbon 
sources, since oxidative phosphorylation is no longer critical for growth. 
PINK1/PARKIN pathway.  Perhaps the most well studied mammalian pathway 
of mitophagy is PTEN-Induced Putative Kinase 1(PINK1)/Parkin cytosolic E3 
ubiquitin ligase-mediated degradation of mitochondria. These two genes are often 
mutated in autosomal recessive Parkinson’s disease (PD). In patients with PD, 
there is an accumulation of dysfunctional mitochondria. In Drosophila models, 
deletion of PINK1 and Parkin proteins causes accumulation of dysfunctional 
mitochondria in neuronal and muscle tissues that results in neurodegeneration91,
92. Subsequent experiments demonstrated that Parkin and PINK1-dependent
mitophagy can be induced by mitochondrial depolarization with carbonyl cyanide 
m-chlorophenyl hydrazone (CCCP)93. In normal ‘’nonstressed” conditions PINK1 
is recruited to mitochondrial membranes by mitochondrial membrane potential and 
undergoes degradation facilitated by mitochondrial processing peptidase and 
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proteases94. In defective mitochondria, where membrane potential is decreased, 
PINK1 is stabilized on mitochondrial membranes and is no longer degraded. This, 
in turn, recruits Parkin, which is normally found in the cytoplasm, to mitochondria95. 
After recruitment to the mitochondrial membrane, Parkin ubiquitinates several 
mitochondrial proteins and initiates mitophagy. Among the ubiquitinated proteins 
are numerous outer membrane proteins, including Mitofusins 1 and 2, MIRO and 
DRP1. Although the exact roles of these ubiquitinated proteins and sites are not 
well understood, they trigger degradation of mitochondrial proteins and whole 
mitochondria by the ubiquitin proteasome system96,97 and autophagic machinery. 
The latter is mediated by recruitment of mammalian homologue of ATG8 (LC3) to 
mitochondrial membranes. Recently, it has been reported that upon stabilization 
on the mitochondrial membranes, PINK1 is autophosphorylated at multiple sites 
that are critical for Parkin recruitment98. PINK1 also phosphorylates Parkin on Ser 
65 and leads to activation of Parkin’s E3 ligase activity99. Moreover, PINK1 can 
phosphorylate Ser65 on ubiquitin molecules which leads to activation of Parkin as 
well100.  Ubiquitinated proteins cannot directly bind to the autophagic machinery, 
and therefore, there are a number of scaffolding proteins that bridge ubiquitinated 
proteins to LC3. To date, Optineurin, NDP52, and p62 have been reported to 
bridge mitochondria and LC3101-103. 
BNIP3 and BNIP3L mediated mitophagy.  Another well recognized mitophagic 
pathway is mediated by BCL2 and Adenovirus E1B 19-kDa-interacting Protein 3 
(BNIP3) and BNIP3-like (BNIP3L, also known as NIX) proteins104. Both are BH3-
only mitochondrial single-pass outer membrane proteins that also contain an LIR 
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(LC3 interacting domain) that binds and facilitates the interaction between 
mitochondria and LC3105, 106. Studies in mice have shown that NIX is critical in 
mitochondrial clearance during erythrocyte development107, 108. In contrast, BNIP3 
is involved in hypoxia and fasting induced mitophagy in the liver109, 110, and BNIP3 
KO mice develop increased mitochondrial mass and dysfunction accompanied by 
excessive accumulation of lipids in the liver111. In addition, phosphorylation of 
BNIP3 on Ser17 and Ser24  increases the affinity for the LC3 interacting domain, 
therefore augmenting mitophagy112. Apart from their mitophagic roles, both BNIP3 
and NIX play important roles in induction of apoptosis. 
FUNDC1 mediated mitophagy.  Recently, FUN14 Domain-Containing Protein1 
(FUNDC1) has been identified as a novel mitophagy receptor. In in vitro studies, 
FUNDC1 mediates hypoxia induced mitophagy, as FUNDC1 KD cells failed to 
induce mitophagy113. FUNDC1 is an outer mitochondrial membrane protein with 
three transmembrane domains that has its N-terminus exposed to the cytoplasm 
and C-terminus extended into the intermembrane space. Mechanistically, studies 
have shown that FUNCD1 has a LIR domain and can interact with LC3. Moreover, 
FUNDC1 is posttranslationally regulated by phosphorylation events. Under 
normoxic conditions, FUNDC1 is phosphorylated by SRC and CK2 at Tyr18 and 
Ser13, which impairs its interaction with LC3. Under hypoxic or uncoupling 
conditions, these phosphorylation events are reversed by the action of 
mitochondrial PGAM5 phosphatase114, therefore enabling the interaction of LC3 
with its binding domain on FUNDC1. In addition to these inhibitory phosphorylation 
events, there is an activation-inducing phosphorylation site, Ser13, that under 
15 
hypoxia is phosphorylated by ULK1115. In addition to posttranslational modification 
of FUNDC1, there is also transcriptional regulation mediated by miRNA 137. 
During hypoxia, there is a decrease in levels of miRNA 137 that leads to 
upregulation of FUNDC1116. 
Cardiolipin mediated mitophagy.  Recently, cardiolipin has been shown to act 
as a mitochondrial degradation receptor in mammalian primary neurons and SH-
SY5Y cells117. Cardiolipin is an inner mitochondrial membrane phospholipid that is 
essential in mitochondrial cristae formation and stabilizes proteins of the ETC. 
Upon treatment with CCCP or either rotenone, staurosporine or 6-
hydroxydopamine, cardiolipin is translocated to the outer mitochondrial membrane 
with the help of the mitochondrial NDPK-D protein118,  where it is exposed to 
cytoplasm. This allows cardiolipin to interact with LC3 and recruit autophagic 
machinery to mitochondria. 
Energetic balance and mitophagy. Mitochondria are pivotal in energy 
metabolism and perform a variety of metabolic functions. Perhaps the most 
important aspect of mitochondrial biology is the ability to produce ATP through the 
ETC that takes place on the inner mitochondrial membrane.  The ETC is often 
leaky, and therefore produces reactive oxygen species by complexes I and III. A 
majority of the cell’s need for ATP is met by mitochondrial oxidative 
phosphorylation, while the rest is supplied through glycolysis. In times of greater 
demand for ATP or when the carbohydrate source can only be metabolized in 
mitochondria, cells increase the mitochondrial load which in turn increases reactive 
oxygen species production. This could be potentially damaging to the cells and to 
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mitochondria as well. In 2013, Melser and colleagues showed that increased 
mitochondrial activity induces mitochondrial degradation mediated by NIX and the 
small GTPase RHEB independently of mTOR119. Importantly, these authors 
showed that RHEB and NIX mediated mitophagy are protective by increasing 
mitochondrial OXPHOS activity, while RHEB and NIX deficiency has deleterious 
effects on mitochondrial function mediated by ROS damage. 
Discussion 
Although mitochondrial degradation via lysosomes was first reported five 
decades ago, there has been little progress in elucidating the role of mitophagy 
and its regulatory networks in health and disease. The majority of mitophagic 
pathways described in this work have been discovered in the last decade. Except 
for a few proteins (PINK1/PARKIN and BNIP3/NIX), the exact mechanisms and 
physiological or pathological roles of mitophagy or its impairment are not well 
understood. Mitochondria are a source and a target of ROS damage, and undergo 
recycling, presumably to avoid excessive damage accumulation. In experimental 
murine and in vitro cell systems, the half-life of mitochondria is estimated to be 
from less than 2 to 10 days120-122. This fast recycling rate requires that efficient 
quality control mechanisms must be present in mitochondria, and that alterations 
in these processes could lead to accumulation of impaired mitochondria. Despite 
the significant rate of mitochondrial turnover, research on mitophagy has primarily 
been focused on mitochondrial toxin-induced mitophagy, and many known 
mediators of mitophagy have been discovered with stressors like CCCP, Antimycin 
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A, and rotenone, and so forth. While these inducers have been powerful tools and 
were instrumental in many discoveries, most cases do not have physiologically 
related conditions, at least when we consider the amplitude of the applied stress. 
For example, some studies have failed to detect Parkin recruitment and mitophagy 
in primary neurons with endogenous Parkin upon depolarization with CCCP123,124. 
Another important aspect of mitophagic research is that in most experimental 
conditions we use stressors that are uniformly applied to all mitochondria in the 
cell, while in physiological conditions mitochondria tend to segregate ‘’bad” parts 
and target them for degradation. This perhaps could be explained by the fact that 
mitophagy has been hard to detect when it is not massively induced. In recent 
years, there has been a surge of new methods to better quantify mitophagy, and it 
should become relatively easy to identify and quantify mitophagy in more 
physiological conditions, as well as pathologies directly connected to impairment 
of mitophagy. There are numerous disease states that often are accompanied with 
mitochondrial dysfunction. Whether mitophagy, an ultimate checkpoint in 
mitochondrial quality, is implicated in these disease states remains to be studied. 
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Abstract 
Abnormal accumulation of TCA cycle metabolites stabilizes hypoxia inducible 
factor 1α (HIF-1α) that results in profound transcriptional and metabolic changes. 
In many cases, accumulation of succinate and fumarate, and subsequent 
stabilization of HIF-1α, is thought to be causative for cancers such as 
paragangliomas, phaeochromocytomas, leiomyosarcoma, and renal cell 
carcinomas. Moreover, lactate and pyruvate, the end products of glycolysis, also 
stabilize HIF-1α by direct inhibition of prolyl hydroxylases, which are required for 
HIF-1α degradation. In this report, we show that in many cancer cell lines 
mitochondrial pyruvate metabolism induces the stabilization of HIF-1α and 
requires mitochondrial entry of pyruvate.  Pyruvate metabolism induces mitophagy 
mediated by HIF-1α and its downstream target BNIP3. We also show that inhibition 
of mitochondrial pyruvate carrier abrogates stabilization of HIF-1α and BNIP3. 
Notably, this pseudohypoxic stabilization of HIF-1α by pyruvate could be induced 
by glycolysis derived pyruvate, suggesting this process could have physiological 
relevance. Moreover, we show that antioxidant N-acetylcysteine (NAC) is sufficient 
to block HIF-1α stabilization. Based on our findings, we propose that stabilization 
of HIF-1α and mitophagy are protective against excessive reactive oxygen species 
(ROS) damage to mitochondria, possibly by removing damaged mitochondria, 
thereby maintaining mitochondrial health. Pioglitazone, a drug that has widespread 
usage in diabetes treatment, abrogates stabilization of HIF-1α caused by 
mitochondrial pyruvate metabolism, likely by inhibition of the mitochondrial 
pyruvate carrier complex. Whether the ability of pioglitazone to block the 
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stabilization of HIF-1α has any clinical significance in type two diabetes treatment 
awaits further investigation. 
Introduction 
The decision to utilize pyruvate through mitochondria or to convert it to lactate 
is one of the crucial steps of cellular carbohydrate metabolism. In differentiated 
cells most of the pyruvate is taken up by mitochondria where it is utilized in the 
TCA cycle1. In contrast, most cancer cells rely on glycolysis2 and divert pyruvate 
to lactate that is excreted from cells3. Furthermore, stem cells appear to rely on 
glycolysis and tend to lose their stemness with increased mitochondrial 
metabolism4,5. In cancer cells, glycolysis supports the increased anabolic 
requirements of cells, while pyruvate to lactate conversion regenerates ample 
NAD+ that, in turn, supports glycolysis. The increased glycolytic dependence of 
cancer cells was first described by Otto Warburg and subsequently is called the 
Warburg effect6. For several decades, cancer cells’ “unwillingness’’ to utilize 
pyruvate in mitochondria was attributed to defective mitochondria, although in 
recent years, several lines of evidence suggest that most cancer cells have fully 
functional mitochondria. Furthermore, studies have shown that the Warburg effect 
is mostly driven by oncogenic mutations and hypoxia. This is evident in solid 
tumors7 where lack of blood flow and subsequent scarcity of oxygen activates 
hypoxia inducible transcription factor 1 ( HIF-1) a key regulator of the oxygen 
sensing pathway. HIF-1 facilitates adaptation to hypoxia at cellular and organismal 
levels. The HIF-1 transcription factor is a heterodimer consisting of alpha and beta 
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subunits, where HIF-1β is constitutively expressed while expression of HIF-1α is 
highly regulated by cellular oxygen tension. With ample cellular oxygen 
concentrations, HIF-1α is hydroxylated8, 9 at two prolyl residues (402 and 564) in 
its oxygen-dependent degradation domain (ODD) by prolyl hydroxylase domain 
(PHD) proteins10.  Proline hydroxylation serves as a recognition signal for the Von 
Hippel–Lindau (VHL) tumor-suppressor protein of the ubiquitin ligase complex, 
that ubiquitinates and targets HIF-1α for proteasomal degradation. Another oxygen 
dependent regulation of HIF-1α activity is asparagine 803 hydroxylation by Factor 
Inhibiting HIF (FIH)  asparaginyl hydroxylase11, 12 , which disrupts the interaction of 
HIF-1α with the p300/CBP coactivator inhibiting its transcriptional activity. Under 
low cellular oxygen tension, the rate of hydroxylation of prolyl residues significantly 
decreases and HIF-1α is not recognized by VHL for ubiquitination. This leads to 
stabilization of HIF-1α and subsequent translocation to nucleus, where the HIF 1 
heterodimer binds to the hypoxia responsive elements in promoter regions of a 
vast number of genes responsible for adaptation to low oxygen levels. HIF-1α 
initiated transcriptional changes lead to organismal level adaptations such as 
increased angiogenesis and red blood cell production, and to cellular responses 
such as increased glycolytic enzyme expression and repression of oxidative 
metabolism. Transcriptional changes induced by HIF-1α could also induce 
carcinogenesis and mediate drug resistance in cancers. It is important to note that 
mitochondria and the TCA cycle are directly involved in regulation of HIF-1α 
stabilization. During the hydroxylation reaction PHDs utilize alpha ketoglutarate 
(αKG), a metabolite of TCA cycle. Any metabolic perturbation that results in a 
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change of αKG levels can potentially influence HIF-1α stabilization. In addition, 
activation of HIF-1α decreases the flow of pyruvate into mitochondria by virtue of 
pyruvate dehydrogenase kinase overexpression and activation that inhibits the 
pyruvate dehydrogenase complex13, 14.  Certain aberrant TCA metabolites are 
known to inhibit prolyl hydroxylases15, 16 and stabilize hypoxia HIF-1α in a variety 
of cancer types17-20. In most cases, inhibition of PHDs are directly linked to 
mutations in the succinate dehydrogenase21, 22, fumarate hydratase23, and 
isocitrate dehydrogenase24 genes. Mutations in both SDH and FH result in 
accumulation of succinate and fumarate respectively, while isocitrate 
dehydrogenase 1 mutations result in a formation of 2-hydroxyglutarate25, a 
competitive inhibitor of PHD 26, and in depletion of αKG, a cofactor in HIF-1α 
degradation. It has also been shown that fumarate reacts with the antioxidant 
glutathione and forms succinated glutathione which eventually leads to excessive 
ROS production and stabilization of HIF-1α27. Furthermore, glucose and glycolysis 
end products lactate and pyruvate can inhibit prolyl hydroxylases and induce the 
hypoxic response28, 29. While there is substantial evidence of pyruvate stabilization 
of HIF-1α, the role of mitochondrial pyruvate metabolism in this process has not 
been elucidated. We wanted to investigate whether inhibitory effects of pyruvate 
on prolyl hydroxylases require mitochondrial metabolism, or whether cytoplasmic 
pyruvate can stabilize HIF-1α directly. Furthermore, glycolytic and TCA cycle 
mediated HIF-1α stabilization have been mostly studied in the context of cancer, 
while the physiological importance of normal glucose metabolism in HIF-1α 
stabilization is not well understood. This is particularly important since in most 
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laboratory settings the majority of model cell lines are grown in 10 to 25 mM 
glucose solution often substituted with 1 mM pyruvate, concentrations that are 
multiples of their physiological values. This could lead to overwhelming the 
mitochondria with pyruvate and lead to metabolic reprograming of the cells. In this 
work, we studied the effects of pyruvate metabolism in context of HIF-1α induction 
and subsequent metabolic changes. 
Results 
Mitochondrial pyruvate metabolism stabilizes HIF-1α 
and induces mitophagy. 
To test whether glycolysis or pyruvate metabolism in mitochondria induce 
stabilization of HIF-1α, we fed different cell lines with either 10 mM glucose or 10 
mM pyruvate. Since pyruvate can only be utilized in mitochondria to produce 
energy via TCA cycle and oxidative phosphorylation, while glucose could be 
consumed by glycolysis to produce pyruvate, we hypothesized that any changes 
seen in HIF-1α stabilization could be attributed to presence or absence of 
glycolysis. In four cell lines, we tested, (HepG2, HEK 293, Hela, and SH-SY5Y) 
pyruvate stabilized HIF-1α after 24 h incubation with 10 mM pyruvate (Figure 3.1, 
A). Interestingly, we noticed that HIF-1α stabilization was the highest in HepG2 
cells. Furthermore, Hela cells had elevated level of HIF-1α with glucose compared 
to other cell lines we tested, but less in intensity than pyruvate treated cells. Since 
the highest level of stabilization was achieved in HepG2 cells, we decided to use 
HepG2 cells as our preferred cell line in further analysis. In HepG2 cells incubation 
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with 10 mM pyruvate noticeably stabilized HIF-1α after 4 h, with gradual increase 
up to 10 h (the last time point in this series of experiments). A slight increase in 
HIF-1α levels was also recorded in glucose treated cells, suggesting that glycolysis 
derived pyruvate could stabilize HIF-1α (Figure 3.1, B). Moreover, we noticed that 
increasing pyruvate concentration results in increased HIF-1α accumulation, but 
at 25 mM concentration this effect was diminished (Figure 3.1, C). Interestingly, 
addition of 10 mM glucose with 10 mM pyruvate completely abrogated stabilization 
of HIF-1α, suggesting that glycolysis can restore degradation of HIF-1α.  HIF-1α is 
known to mediate mitophagy 30, partially through upregulation of 
BCL2/Adenovirus E1B 19kDa Interacting Protein 3 (BNIP3)31, 32. In our 
experiments, we noticed increased expression of BNIP3 and a decrease in 
mitochondrial proteins VDAC1, FUNDC1, and TIM23 (Figure 3.1, B and C).  
Importantly, addition of 10 mM glucose to pyruvate blocked stabilization of HIF-1α 
and reduced the expression of BNIP3, suggesting that HEPG2 cells prefer 
glycolysis over oxidative phosphorylation, and further implying that HIF-1α 
stabilization is dependent on mitochondrial respiration rather than pyruvate 
presence in the cytoplasm. Moreover, glucose addition restored the levels of 
mitochondrial proteins. Treatment with Echinomycin, a HIF-1α inhibitor, 
significantly decreased the expression of BNIP3, suggesting BNIP3 expression is 
under direct control of HIF-1α. Furthermore, in Hela cells, knockdown of HIF-1α 
abrogates expression of BNIP3 after pyruvate treatment and increases 
mitochondrial protein levels as measured by western blotting (Figure 3.2).  To 
further test whether HIF-1α stabilization is due to the mitochondrial pyruvate 
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metabolism, we incubated HepG2 and Hela cells with glucose and pyruvate as 
before, but with addition of mitochondrial pyruvate carrier inhibitor UK5099 33, 34. 
Addition of UK5099 abrogated stabilization of HIF-1α and expression of BNIP3 
protein, confirming that HIF-1α stabilization is dependent on mitochondrial entry of 
pyruvate (Figure 3.3, A and B). Interestingly, inhibition of lysosomal V-ATPases 
with 100nM Bafilomycin A1 markedly increased stabilization of HIF-1α, suggesting 
that HIF-1α is at least partially degraded via lysosomes35.  UK5099 significantly 
increased glucose clearance from the media with HepG2 cells, suggesting that 
even with glycolysis HepG2 cells use some of the pyruvate derived through 
glycolysis in mitochondria (Figure 3.3, C). In contrast, UK5099 significantly 
decreased the clearance of pyruvate from media, although it did not reach the level 
of initial pyruvate concentration. Moreover, addition of UK5099 to glucose 
incubated cells increased the acidification of the media, indicating that blocking 
mitochondrial pyruvate metabolism increases cellular needs for glycolysis, 
presumably to meet energetic needs of the cell. In contrast, there was no 
acidification of media while grown on pyruvate with or without UK5099. This was 
also evident from metabolomics analysis, where we found negligible amounts of 
lactate in pyruvate fed cells when compared to glucose fed cells (Figure 3.4). This 
finding is particularly surprising since HIF-1α upregulates the expression of lactate 
dehydrogenase A (LDHA) 36 and should have increased conversion of pyruvate to 
lactate. It has been reported that increased levels of pyruvate can inhibit the lactate 
dehydrogenase enzyme37-39. Although we did not test this hypothesis, it is possible 
that pyruvate inhibits LDH in our system as well. To test whether the ability of 
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UK5099 to destabilize HIF-1α is indeed due to its effects on mitochondria and not 
HIF-1α itself, we incubated cells with an iron chelator deferiprone with or without 
UK5099. Under iron chelation UK5099 failed to block the stabilization of HIF-1α, 
indicating that UK5099 cannot rescue iron deficiency. 
Mitochondrial pyruvate metabolism increases 
TCA cycle metabolites 
Since many TCA cycle metabolites are known to stabilize HIF-1α, we 
questioned whether that would be a mechanism of HIF-1α stabilization in our 
model system. To identify possible metabolite(s) responsible for HIF-1α 
stabilization, we incubated HepG2 cells with pyruvate and glucose for 24 h and 
subjected the cells to metabolomics analysis using gas chromatography-mass 
spectrometry (GC-MS). All TCA metabolites that have been shown to inhibit PHDs 
were increased with pyruvate treatment. Succinate was increased by 3.8-fold, 
while fumarate and malate were increased by 6.8 and 12-fold respectively (Figure 
3.5, A). In addition, we measured a 10-fold increase in 2-hyroxyglutarte levels.  2-
hydroxyglutarete is a competitive inhibitor of prolyl hydroxylases, but in the 
presence of a high level of alpha ketoglutarate is unable to inhibit αKG-dependent 
dioxygenases26, 40.   There was also a 59-fold increase in alpha ketoglutarate 
levels, which is a cofactor the in HIF-1α hydroxylation reaction. These findings are 
particularly surprising since αKG is known to alleviate pseudohypoxia induced by 
high levels of succinate and fumarate 41. Since αKG was the most upregulated 
TCA metabolite in our screen, we suspected there could be an inhibition of alpha 
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ketoglutarate dehydrogenase (OGDH) enzyme. This was confirmed by 
assessment of enzymatic activity of OGDH in isolated mitochondria from cells 
incubated with either 10 mM glucose or pyruvate for 24 h. We found that OGDH 
activity is decreased by 80% after pyruvate treatment, while citrate synthase 
activity was decreased slightly (11%) (Figure 3.5, B). We wanted to know whether 
inhibition of   OGDH and PDH, and therefore inhibition of the TCA cycle, will rescue 
the HIF-1α stabilization phenotype. Treatment with CPI 630, a lipoic acid derivative 
that inhibits OGDH and pyruvate dehydrogenase complex 42, was sufficient to 
block the induction of HIF-1α (Figure 3.5, C), confirming that functional TCA cycle 
is needed for stabilization of HIF-1α. High levels of αKG in our system suggested 
that succinate and fumarate are unlikely to mediate stabilization of HIF-1α due to 
their presumed competitive binding to PHDs against αKG. Nevertheless, we tested 
whether succinate, fumarate (methyl and ethyl esters), αKG, or citrate could 
stabilize HIF-1α in HepG2 cells. None of the tested metabolites could stabilize HIF-
1α to the levels comparable with pyruvate (Figure 3.5, D). Interestingly, dimethyl 
ketoglutarate (2MKG), an ester of αKG that is widely used as cell permeable 
analog of αKG, stabilized HIF-1α, and this stabilization could not be blocked with 
UK5099 (Figure 3.6, A).   This compound also induced mitophagy in Hela cells 
after 24 h incubation as measured by mito-Rosella43  (Figure 3.6, B).  It has been 
reported that 2MKG directly inhibits prolyl hydroxylases, independently of its 
property to increase intracellular αKG concentrations44, 45. 
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Cellular production of pyruvate is sufficient to stabilize HIF-1α 
In our initial experiments with HepG2 cells, significant stabilization of HIF-1α 
was achieved only with supraphysiological concentrations of pyruvate (2 to 10 
mM), while cellular pyruvate levels are reported to be around 200 µM46 and 
circulating pyruvate levels in blood are about 50 µM47. Although this is an 
interesting observation, it hardly could be applied to any physiological condition.  
In contrast to HepG2 cells, 10 mM glucose was sufficient to stabilize HIF-1α in 
Hela cells. Importantly, this observation is also dependent on pyruvate and its 
mitochondrial metabolism, since treatment with UK5099 completely abrogated 
stabilization of HIF-1α (Figure 3.3, A). This observation is particularly significant 
since it implies that stabilization of HIF-1α could be achieved with pyruvate derived 
from glycolysis. Since both glucose and pyruvate induced HIF-1α, as a control 
treatment for Hela cells we used all deficient (no carbon source) media or 10 mM 
glutamine containing media. Both media did not stabilize HIF-1α, nor induce 
expression of BNIP3 (Figure 3.3, D). Although glutamine should feed into the TCA 
cycle by glutaminolysis, it did not change HIF-1α protein levels, suggesting that 
mitochondrial metabolism per se is not sufficient to induce HIF-1α. 
As another pharmacological inhibitor of the MPC complex, we used 
pioglitazone48, 49, a member of thiazolidinedione family of insulin sensitizers. As 
expected, pioglitazone abrogated stabilization of both glucose and pyruvate 
induced HIF-1α stabilization and BNIP3 expression. To test whether pioglitazone 
inhibits HIF-1α stabilization by inhibition of MPC1 and not due to its PPAR-Υ 
agonist properties, we incubated cells with 10 mM methyl and ethyl pyruvate with 
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and without pioglitazone. These esters can freely cross mitochondrial membranes 
and are cleaved in the matrix of mitochondria to generate pyruvate.  In these 
settings pioglitazone was unable to block the stabilization of HIF-1α and BNIP3, 
confirming that HIF-1α stabilization is dependent on mitochondrial pyruvate 
metabolism (Figure 3.7). Furthermore, we noticed that pyruvate treatment in Hela 
cells induces selective degradation of OGDH, while HSP60 protein levels were not 
changed to the same extent. Moreover, addition of pioglitazone or NAC can restore 
the levels of OGDH, suggesting that this process is mediated by mitochondrial 
pyruvate metabolism and production of ROS (Figure 3.8). 
Pyruvate metabolism induces ROS 
Another widely reported mechanism of HIF-1α stabilization is mediated by 
Reactive Oxygen Species (ROS). Reactive oxygen species could inhibit prolyl 
hydroxylases and stabilize HIF-1α50 or at least they are required for HIF-1α 
stabilization51-54.  OGDH is a significant ROS producer and has been reported to 
be a source and a target of ROS55-57. Another closely related 2-oxoacid 
dehydrogenase complex, pyruvate dehydrogenase, has been reported to produce 
ROS as well58.  To test whether this mechanism could be responsible for induction 
of HIF-1α stabilization in our model, we first tested whether pyruvate increases the 
mitochondrial membrane potential when compared to glucose in HepG2 cells 
(Figure 3.9, A).  Pyruvate induced an increase in the mitochondrial membrane 
potential that can be reversed with addition of UK5099, indicating increase 
oxidative phosphorylation activity. As expected, superoxide production was 
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increased with pyruvate incubation as measured with dihydroethidium (DHE) 
staining, but UK5099 failed to decrease the amount of superoxide detected (Figure 
3.9, B and C). Although this is counterintuitive, similar results were obtained by 
other groups as well and were attributed to antioxidant properties of pyruvate 
itself59, 60.  Nevertheless, addition of the antioxidant N-acetyl cysteine (NAC) was 
sufficient to disrupt the stabilization of HIF-1α in HepG2 cells (Figure 3.9, D) and 
in Hela cells (not shown). Since UK5099 failed to decrease the production of ROS 
but was sufficient to stop the stabilization of HIF-1α, we speculate that ROS alone 
is not a sufficient to induce HIF-1α. Moreover, we treated the cells with antimycin 
and rotenone to induce ROS, and both drugs were unable to induce HIF-1α in 
HepG2 cells. Of interest, Rotenone and Antimycin treatment in combination with 
10 mM pyruvate disrupted stabilization of HIF-1α. 
Conclusion 
In this body of work, we identified that mitochondrial pyruvate metabolism is 
sufficient to stabilize HIF-1α, and it can be regulated by manipulation of the 
mitochondrial pyruvate carrier. We also showed that antioxidants can abrogate this 
stabilization, although induction of ROS was not a sufficient condition to replicate 
HIF-1α stabilization. Surprisingly, feeding mitochondrial metabolism with 
succinate, fumarate, or αKG did not replicate HIF-1α stabilization, suggesting that 
TCA cycle entry point is critical for this phenomenon. Another possible mechanism 
that we did not test was the elevated levels of TCA cycle metabolites along with 
ROS and 2-hydroxyglutarate; perhaps they could all act in concert to stabilize HIF-
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1α. This type of conditions could be virtually impossible to recreate. The 
observation that pioglitazone inhibits stabilization of HIF-1α is particularly 
interesting, since pioglitazone and other TZD family medications are still 
prescribed to treat diabetes. 
Discussion 
Stabilization of  HIF-1α by low oxygen tension upregulates glycolytic genes61 
and reduces pyruvate utilization by mitochondria. This is partially mediated by 
inhibitory phosphorylation of pyruvate dehydrogenase by pyruvate dehydrogenase 
kinase and by increased shunting of pyruvate to lactate. In hypoxia, this 
phenomenon is critical for cellular homeostasis and serves to match the available 
oxygen to substrate oxidation. However, during pseudohypoxia, stabilization of 
HIF-1α under ample oxygen availability could not serve this purpose. Increased 
pyruvate uptake by mitochondria is thought to increase the activity of OXPHOS 
and as a byproduct, increase the production of reactive oxygen species62, 63. Here, 
we suggest that activation of hypoxic response by pyruvate metabolism could be 
a defense mechanism against excessive ROS production and cellular damage. 
We suggest that the hypoxic response is activated to limit the flow of pyruvate to 
mitochondria and limit the ROS production. Mitophagy mediated by HIF-1α could 
be another way to keep the mitochondrial pool healthier by degrading damaged 
mitochondria. A similar hypothesis has been tested by Melser and colleagues 
where they showed that cells grown on glutamine exhibit increased mitophagy 
mediated by RHEB and NIX, and abrogation of mitophagy results in more ROS 
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damage 64.  HIF mediated protective mechanisms against oxidative injury have 
been reported in kidney and intestine during ischemia and reperfusion65, 66 . 
Moreover, it has been shown that metabolic reprogramming by HIF-1α reduces 
ROS levels in murine cancer models as well67. 
Traditionally, stabilization of HIF-1α by means other than hypoxia has been 
considered a pathological state. Our observation that mitochondrial pyruvate 
metabolism can stabilize HIF-1α even when cells are treated with 10 millimolar 
glucose is interesting. It is possible that low steady state levels of HIF-1α can 
contribute to mitochondrial homeostasis by activating basal mitophagy and by 
regulating pyruvate flow to mitochondria. Moreover, we show that pioglitazone, a 
diabetes medication that is still in use, could reverse mitochondrial pyruvate 
induced HIF-1α stabilization. Pioglitazone and other medications of the same 
family have an extensive list of side effects ranging from bone density lose to fluid 
retention and cardiovascular risks. It remains to be studied whether beneficial or 
side effects of TZDs are somehow connected to their ability to inhibit stabilization 
of HIF-1α. 
Materials and methods 
Cell culture 
Hela, HEK-293, HepG2, and SH-SY5Y cells were from ATCC (American Type 
Culture Collection), and cultured in DMEM (Life Technologies) with 10% heat-
inactivated fetal bovine serum (Atlanta Biologicals), penicillin, and streptomycin 
(Life Technologies), and maintained in a 5% CO2, 37OC humidified incubator. 
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Custom formulated media was made by addition of different carbon sources to 
DMEM without glucose, pyruvate, and amino acids (US Biological) and pH was 
corrected to 7.4. Methyl and ethyl pyruvate, pyruvate, glucose, galactose, dimethyl 
alpha-ketoglutarate, dimethyl and diethyl esters of succinate and fumarate, were 
obtained from Sigma.    
Expression plasmids and siRNA transfection 
Mito-Rosella was previously described43. Briefly, cells were seeded in 12 well 
plates and transfected with mito-Rosella upon 80% confluency. Cells were 
transfected with Polyjet transfection reagent (Signagen). After 48 h cells were 
washed with PBS twice and incubated with experimental media, with addition of 
E64/Leupepeptin cocktail, to prevent lysosomal degradation. Cells were assessed 
for mitophagy after 24 h incubation and imaged with EVOS-fi inverted LED 
fluorescence microscope. ImageJ software were used for quantitative analysis. 
SiRNA transfections were carried out with Rnaimax transfection reagent 
(Invitrogen), per manufacturer’s instruction. Gene knockout was tested after 48 h 
of incubation.  SiRNAs HIF-1α and scrambled control were purchased from 
Invitrogen. SiRNA against BNIP3 were synthesized in University of Utah DNA 
synthesis core and had the following sequence: 5’-
GGACGAAGUAGCUCCAAGATT-3 and (reverse) 5’-
UCUUGGAGCUACUUCGUCCTT-3’. 
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Mitochondrial membrane potential and ROS 
production assessment 
Mitochondrial membrane potential and ROS production were measured by 
TMRE and DHE (Life Technologies), per the manufacturer’s instructions, using a 
BD FACSCanto analyzer on high throughput mode. For ROS production analysis, 
cells were grown on 12 well plates until reaching 90% confluency and loaded with 
DHE for 15 min, washed 3 times with PBS and incubated with experimental media 
for indicated durations. For TMRE fluorescence intensity analysis, cells first were 
incubated with experimental conditions for 6 h, then incubated with TMRE for 15 
min. Cells were harvested for analysis by washing twice with PBS, trypsinizing and 
transferring to 96 well plate wells containing 0.3 mL PBS and fluorescent intensities 
were measured by FCM. For all conditions, 3 biological replicates with at least 
10000 cells were used. Oligomycin and CCCP were used as positive and negative 
controls for TMRE. Antimycin A and antimycin A plus NAC were used as controls 
for DHE experiments. 
Antibodies and chemicals 
Primary antibodies used in this study:  mouse anti-HIF1α(# 610958), rabbit 
anti-BNIP3, rabbit anti-LC3A/B, rabbit anti-HSP60, rabbit anti-MPC1, rabbit anti-
OGDH (Cell Signaling, #44060S, #4108S, #12165S, #14462S, and #13407S); 
mouse anti-TIM23 (1:1000, BD Biosciences, product #611222); mouse anti-
VDAC1, mouse anti-TOM20, rabbit anti-SDHB (Santa Cruz, 1: 500, sc-58649, sc-
17764, sc-25851); rabbit anti-ATP synthase gamma (GeneTex, product #GTX-
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114275), rabbit anti-FUNDC1(Aviva Systems Biology, # ARP53280_P050)  mouse 
anti-βTubulin ( Genescript, product # A01410).  Secondary antibodies were:  HPR 
conjugated goat anti-rabbit and goat anti-mouse (1:2500, products #170-6515 and 
#172-1011, respectively).  Bafilomycin A1 was obtained from LC Laboratories. 
Mitotracker Deep Red FM, DHE, TMRE, and Hoechst 33342 were obtained from 
Life Technologies. 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone (Diferiprone) was from 
Sigma. Echniomycin, UK5099 and pioglitazone were purchased from Cayman 
Chemicals. Rosiglitazone and ciglitazone were purchased from Sigma. 
Western blot analysis 
Cells were washed with phosphate buffered saline twice and scraped off the 
plate with RIPA buffer (Santa-Cruz) containing protease/phosphatase cocktail 
(Santa-Cruz). Lysates were incubated on ice for 30 min with gentle, constant 
agitation, then centrifuged at 12,000 ×g for 20 min at 4 ºC to pellet nuclei and other 
insoluble material.  Equal amount of proteins were reconstituted in Novex sample 
buffer and heated 10 min at 90ºC. SDS-PAGE was performed on 4-12% Tris-Bis 
gels (Life Technologies) with MES-based running buffer containing antioxidant 
additive, per the manufacturer's instructions. Gels were transferred to 
nitrocellulose (iBlot system, Life technologies). Nitrocellulose membranes were 
blocked with 5% BSA in TBS containing 0.2% Tween 20, and incubated with 
primary antibodies overnight. The following day membranes were washed and 
incubated with HPR conjugated secondary antibodies for an hr. GeneGnome 
imager (Syngene) was used for imaging of western blot membranes and band 
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intensities were quantified using Gene Snap software (Syngene). 
Metabolomics 
Cells were trypsinized and washed twice with ice-cold PBS and snap frozen in 
liquid nitrogen. Metabolites were extracted with 90% methanol and dried in a 
speed-vac. Analysis was performed with a Waters GCT Premier mass 
spectrometer coupled with an Agilent 6890 gas chromatograph and a Gerstel 
MPS2 auto sampler.  Data were collected and analyzed using QuanLynx, and 
MassLynx 4.1 software. For all conditions, at least five biological replicates were 
analyzed. 
Enzyme activity assays 
Semipure mitochondria obtained by differential centrifugation were used for 
citrate synthase and OGDH activity assays. The citrate synthase activity assay 
was obtained from Sigma. The OGDH activity assay was performed as described 
in Lei and Cooper68. 
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Figure 3.1. Pyruvate stabilizes HIF-1α and induces expression of BNIP3 
A) Hela, HEK 293 and HepG2 cells were treated for 24 h with either 10mM of
glucose or 10 mM pyruvate and HIF-1α stabilization was assessed by western 
blots. Pyruvate stabilized HIF-1α in all cell lines, while glucose stabilized HIF-1α in 
Hela cells. B)  HepG2 cells were treated with 10 mM glucose and 10 mM pyruvate 
for indicated times. Pyruvate induced stabilization of HIF-1α while reducing 
mitochondrial proteins HSP60, VDAC1, and FUNDC1. C) Dose dependent 
stabilization of HIF-1α and BNIP3 expression by pyruvate in HepG2 cells after 24 
h of treatment. Addition of 10 mM glucose to 10 mM pyruvate completely abrogates 
stabilization of HIF-1α and decreases the expression of BNIP3. Increased pyruvate 
concentration correlates with decreased mitochondrial proteins TIM23 and 
VDAC1. 
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Figure 3.2. Expression of BNIP3 and mitophagy are mediated by HIF-1α: Hela 
cells were transfected with siRNAs against HIF-1α and BNIP3 and after 48 h were 
incubated with 10 mM glutamine or 10 mM pyruvate. After 24 h cells were 
harvested and western blot was performed. In the absence of HIF-1α pyruvate was 
unable to increase the expression of BNIP3. There is also marked increase in 
MPC1, TIM23 and SDHB proteins in the absence of HIF-1α. 
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Figure 3.3. HIF-1α stabilization is dependent on mitochondrial pyruvate 
metabolism: A). Hela cells were incubated for 24 h with either 10mM of glucose 
or 10 mM pyruvate and HIF-1α stabilization and BNIP3 expression was assessed 
by WB. With both treatments 200 nM UK5099 blocked the stabilization of HIF-1α 
and decreased the expression of BNIP3. B) HepG2 cells were incubated for 24 h 
with either 10mM of glucose or pyruvate and HIF-1α  stabilization and BNIP3 
expression was assessed by WB. 200 nM UK5099 could block the stabilization of 
HIF-1α. C) Clearance of pyruvate and glucose from media after 24 h incubation 
with UK5099 D) Starvation or 10mM Glutamine do not stabilize HIF-1α  and BNIP3, 
indicating that mitochondrial metabolism (TCA cycle) is not sufficient for induction 
of HIF-1α. In contrast, UK5099 and pioglitazone can downregulate the stabilization 
of HIF-1α and BNIP3.  
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Figure 3.4. Glucose and glycolysis product levels: Pyruvate, lactate, and 
glucose levels in glucose and pyruvate treated HepG2 cells after 24 h. Pyruvate 
levels are not different, indicating that majority of cellular pyruvate is converted to 
TCA cycle intermediates. Lactate is almost undetectable in pyruvate treated cells. 
As expected there was no glucose present in pyruvate treated cells. 
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Figure 3.5. Pyruvate metabolism inhibits OGDH in HepG2 cells: A) Fold 
changes of metabolites (Pyr treated/ Glu treated) after 24 h of incubation with 
Glucose or Pyruvate.  B) Enzymatic activity of OGDH and citrate synthase after 24 
h of incubation with 10 mM Glucose or Pyruvate. C) Pyruvate dehydrogenase 
(PDH) and α-ketoglutarate dehydrogenase (OGDH) inhibitor CPI 613 abrogates 
stabilization of HIF-1α  and restores mitochondrial protein levels D) Stabilization of 
HIF-1α   is not replicated with either succinate and fumarate, citrate (10 mM), 
glutamine (10 mM). ***p<0.0005, **p<0.005, calculated by student’s t-test. 
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Figure. 3.6. Dimethyl 2-ketoglutarate induces stabilization of HIF-1α and 
mitophagy.  A) HepG2 cells were treated with either 10 mM pyruvate or 2 mM of 
dimethyl 2-ketoglutarate (DMKG) separately or together, with varying 
concentrations of UK5099 and HIF-1α stabilization and BNIP3 expression were 
assessed after 24 h with western blotting. UK5099 can inhibit stabilization of HIF-
1α induced by pyruvate, but not HIF-1α  induced by DMKG or DMKG or pyruvate. 
B) Representative images of mito-Rosella transfected Hela cells, treated either
with 10 mM glucose or 2mM DMKG with and without 100 nM of Bafilomycin A1. 
Red fluorescence corresponds to mitochondria delivered to lysosomes for 
degradation.     
71 
Figure 3.7. TZDs are effective inhibitors of pyruvate mediated 
pseudohypoxia. Hela cells were treated with indicated carbon source and 
pyruvate with and without pioglitazone, rosiglitazone and ciglitazone. All three 
could inhibit stabilization of HIF-1α and BNIP3, with Rosiglitazone being the least 
effective. Pioglitazone was not sufficient to inhibit stabilization of HIF-1α induced 
by esters of pyruvate, indicating that mitochondrial pyruvate metabolism is 
essential for the stabilization of HIF-1α. 
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Figure 3.8. Pyruvate induces degradation of OGDH that is reversed by 
pioglitazone and NAC. A) Hela cells were incubated with 10 mM of glutamine or 
pyruvate and pyruvate plus 10 µM pioglitazone for 24 h and western blot was 
performed. Pyruvate induces decrease in OGDH that can be reversed with 
pioglitazone. B) Hela cells were incubated with 10 mM of glutamine or pyruvate 
with increasing concentration of NAC. 5 mM NAC is sufficient to block the 
degradation of OGDH.  
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Figure 3.9. Pyruvate metabolism increases ROS production: A) TMRE 
fluorescence intensities as measured with flow cytometry after 6 h incubation with 
indicated conditions, pyruvate induces increase in mitochondrial membrane 
potential in HepG2 cells. B) Representative images of Mitotracker Deep Red FM 
and DHE loaded HepG2 cells after 6 h of incubation with 10 mM glucose or 
pyruvate.  C) DHE fluorescence intensities as measured with flow cytometry after 
6 h incubation with indicated conditions.  D) Antioxidant NAC blocks the 
stabilization of HIF-1α. *p< 0.05 between pyruvate and glucose treated cells, #p< 
0.05 between pyruvate and pyruvate plus UK5099 treated cells. 
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Mito-Rosella 
Mitochondrial quality control and particularly mitochondrial degradation 
recently has gained more attention as a significant component of cellular and 
organismal homeostasis.  In the last decade, there were many substantial 
discoveries connecting mitophagy to human disease. Identification of Parkinson’s 
disease related proteins PINK1 and Parkin involvement in mitochondrial 
degradation is one example.  Moreover, PINK1 and Parkin are now shown to be 
involved in many other physiological and pathophysiological processes such as 
cancers1-4  and heart function 5-8.  BNIP3, another mitophagic protein, is implicated 
in liver health and BNIP3 deficient mice exhibit increased inflammation and 
steatohepatitis9 . Together these findings underline the importance of mitophagy 
in human health and disease. Despite to these important findings, our 
understanding of mitophagy is not complete. This partly could be explained by the 
limited scope of the methods used to identify mitophagy. In this body of work, we 
have developed pH sensor, Rosella-based rapid and sensitive method of 
mitophagy detection that detects delivery of mitochondria to functional lysosomes. 
Moreover, this method could be applied to single cell analysis as well as to high 
throughput screenings and allows direct comparison of mitophagy to autophagy. 
Single cell analysis is particularly useful in applications that induce minimal 
mitophagy, while high throughput analysis is suitable for more robust mitophagy 
inducers like iron chelation and CCCP. Additionally, this method allows for 
continuous monitoring of mitophagy in cells, since it does not require cell fixation. 
Currently, the method we developed is used in number of laboratories across the 
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world to identify new regulators of mitophagy. Additionally, there are efforts to 
develop transgenic mouse expressing mito-Rosella. This will allow researchers to 
examine mitophagy at an organismal levels in various murine disease models. 
Furthermore, mito-Rosella was instrumental in identification of pyruvate as an 
inducer of HIF-1α and mitophagy that was described in Chapter 3. 
Mitochondrial pyruvate metabolism induces 
pseudohypoxia and mitophagy 
Stabilization of hypoxia inducible factor 1α is indispensable for adaptations to 
hypoxia. However, HIF-1α is also implicated in tumorigenesis and proliferation of 
cancer cells. In different tumors and experimental cancer models, HIF-1α can be 
stabilized by several mechanisms, including hypoxia, mutations in HIF-1α 
degradation pathway genes, and aberrant accumulation of TCA cycle metabolites 
and byproducts. It has been shown that glycolysis end products can also stabilize 
HIF-1α by direct inhibition of prolyl hydroxylases. In this report, we uncovered yet 
another mechanism of HIF-1α stabilization that requires mitochondrial pyruvate 
metabolism. Moreover, we showed that inhibition of the mitochondrial pyruvate 
carrier by UK5099 or by pioglitazone can restore the degradation of HIF-1α. This 
stabilization is also dependent on the presence of reactive oxygen species since 
antioxidant NAC and ascorbic acid can restore the degradation of HIF-1α. 
Interestingly, feeding mitochondria with substrates such as succinate, fumarate, 
and glutamine is not sufficient to induce stabilization. We conclude that 
mitochondrial metabolism itself is not sufficient to induce stabilization of HIF-1α, 
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and specifically requires pyruvate as a substrate.  Moreover, we showed that 
pyruvate that is derived from glycolysis is sufficient to induce this process. The last 
observation is particularly interesting since it implies that stabilization of HIF-1α 
could potentially take place in normal cellular conditions without external sources 
of pyruvate. 
Future directions 
Why does pyruvate induce stabilization of HIF-1α? Mitochondrial pyruvate 
metabolism increases OXPHOS activity by supplying NADH and FADH2. This, in 
turn, should increase the production of ROS by OXPHOS, which is damaging to 
mitochondria themselves as well as to other cellular compartments. Stabilization 
of HIF-1α could limit the damaging effects of ROS by two distinct mechanisms. 
First, since HIF-1α induces mitophagy, it is possible that stabilization of HIF-1α and 
subsequent mitophagy are designed to digest defective mitochondria that arise 
from ROS damage. Second, HIF-1α is also known to inhibit oxidative metabolism 
by upregulation of glycolysis and by inhibition of pyruvate dehydrogenase complex 
that results in decreased pyruvate uptake by mitochondria. Future studies will 
determine whether HIF-1α plays protective role from ROS damage. Additionally, 
the observation that pioglitazone and other TZD members can inhibit stabilization 
of HIF-1α by pyruvate opens several questions that remains to be studied. Are 
TZDs’ abilities to inhibit mitochondrial pyruvate metabolism and promote 
degradation of HIF-1α involved in their pharmacological effects? Could they be 
used to promote HIF-1α degradation and decrease tumor burden in SDHB and FH 
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mutated cancer models? We believe that these questions warrant future studies 
and will broaden our understanding of HIF-1α involvement in cellular homeostasis 
under non-hypoxic conditions.   
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